Evaxion Secures Gates Foundation Grant for Innovative Polio Vaccine

The latest update is out from Evaxion Biotech ( (EVAX) ).

On June 3, 2025, Evaxion A/S announced it received grant funding from the Gates Foundation to design a new polio vaccine. This initiative aims to eradicate polio by leveraging Evaxion’s AI-Immunology™ platform to develop a safer and more effective vaccine that does not rely on live viruses, addressing the risk of a global polio resurgence. The grant will cover the research costs, allowing Evaxion to advance its platform without additional financial burden.

The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall score is primarily influenced by its strong earnings call and technical indicators, suggesting positive momentum and strategic progress. However, financial instability and valuation challenges weigh down the score, highlighting the risks associated with its current financial position.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company focuses on creating novel immunotherapies for cancer, bacterial diseases, and viral infections using its proprietary AI platform, AI-Immunology™. Evaxion has developed a clinical-stage oncology pipeline and a preclinical infectious disease pipeline targeting high unmet medical needs.

Average Trading Volume: 84,190

Technical Sentiment Signal: Sell

Current Market Cap: $3.82M

For an in-depth examination of EVAX stock, go to TipRanks’ Stock Analysis page.